Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.23
- Piotroski Score 2.00
- Grade Buy
- Symbol (VIR)
- Company Vir Biotechnology, Inc.
- Price $7.11
- Changes Percentage (2.3%)
- Change $0.16
- Day Low $6.88
- Day High $7.27
- Year High $13.09
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $28.19
- High Stock Price Target $35.00
- Low Stock Price Target $15.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.01
- Trailing P/E Ratio -2.8
- Forward P/E Ratio -2.8
- P/E Growth -2.8
- Net Income $-615,061,000
Income Statement
Quarterly
Annual
Latest News of VIR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Rightway partners with Curai Health to offer AI-driven virtual urgent care
Healthcare provider Rightway has partnered with Curai Health to use AI in reducing costs and improving patient outcomes. The collaboration offers 24/7 virtual urgent care through Curai's AI-driven cli...
By Yahoo! Finance | 19 hours ago -
For slumping Bears, 'virtual history tour' of Halas Hall can't mask reality of this season
The Chicago Bears offer a virtual history tour of their Halas Hall headquarters, allowing fans to explore the lobby and memorabilia for free. Despite a season of hope, the team faces challenges with r...
By The New York Times | 20 hours ago -
UCF plays No. 19 Wisconsin in White Sulphur Springs, West Virginia
Sign up for AP Top 25 Poll Alerts to receive the latest updates in your inbox. UCF will face No. 19 Wisconsin in a game where the Badgers are favored by 5.5 points with an over/under of 148.5....
By AP NEWS | 21 hours ago
